CEO Reid Waldman walks us through the company's treatment, VDPHL01, which is an extended-release oral formulation of minoxidil, and he sets the table for three key readouts the company has coming up. Plus, the company's regulatory strategy and how he sees the commercial market.

He discusses the launch of brepocitinib in dermatomyositis, which is underway right now, and shares an update on mosliciguat in pulmonary hypertension and learnings from the most recent readout of IMVT-1402 (FcRn).

CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity. Coverage brought to you by

CEO David Veitch discusses Cresemba and Zevtera, both of which have momentum in what used to be market with structural barriers to commercial success, but no longer are in key geographies. Plus, a key phase 3 that will read out for Basilea's next mold infection program, fosmanogepix, in 2028. Coverage brought to you by

PureTech CEO Robert Lyne and Co-Founder Eric Elenko share an update on PureTech and discuss the galectin-9 target and what is next for this program.

Chris Hollowood, Founder of Beacon and CEO of Syncona, describes the top line result and its significance. This is the first pivotal trial in X-linked retinitis pigmentosa to achieve its primary endpoint.

She highlights the company's next generation EGFR, which is in the clinic and reported early stage data at World Lung today, and she describes her goal with the company's Pan-KRAS inhibitor, which is still preclinical. Coverage brought to you by

CEO Paul Peter Tak walks us through how the data has settled, and the steps the company needs to take before officially filing the BLA in Q4. Plus, an update on lung cancer. Coverage brought to you by

Founder & CEO Niels Riedemann describes what he believes was lacking in design for the competitor, avacopan, which has been pulled from the market in many geographies and is currently in contention at FDA, and how izicopan was built to be different. Now InflaRx needs to prove this to investors and regulators of this. Coverage brought to you by

Pascal Prigent describes the test, which can be used both do diagnose patients and to monitor them. On the therapeutics side, he also discusses IQIRVO, which is marketed by Ipsen, and GENFIT's R&D work in oncology and liver failure. Coverage brought to you by

Co-Founder and CEO Ben Oakes describes the difference between Scribe's approach and the first generation of CRISPR technologies. He then discusses the PCSK9 program, which harnesses epigenetic silencing, and preclinical work on Lp(a) and APOC3. Coverage brought to you by

CEO Chris Peetz describes the vision for the company, and its acquisition of Bluejay, which will have phase three readouts both this quarter and next. Plus, his explanation of discussions with FDA on volixibat, and more phase 3 data that is scheduled this year on LIVMARLI. Coverage brought to you by

CEO Allan Rein describes the proof of concept Prime has achieved with two patients in Chronic Granulomatous Disease, and discusses the companies plans in Wilson's Disease, Alpha-1 Antitrypsin Deficiency, and Cystic Fibrosis. Coverage brought to you by

He discusses the financing dynamics of the biotech market currently, and comments on whether generalist investors are starting to participate in the sector again. Coverage brought to you by

OV329, the GABA-AT inhibitor, will have photosensitivity data over the coming months while OV4071, the KCC2, will start a ketamine challenge study by the end of the year that should give visibility to a host of important biomarkers to better understand its profile. Coverage brought to you by

CEO Jonathan Dickinson explains the rationale for the Sobi deal and what it means for the development of lacutamab. Plus, preparing for the monalizumab readout and why Innate believes its Nectin 4 is well differentiated and compelling. Coverage brought to you by

Co-Founder & CEO Jennifer Good shares her take on recent clinical disappointments in the chronic cough space and describes how Trevi's therapy, Haduvio, is different. Plus, an overview of the clinical timelines. Coverage brought to you by

Founder and CEO Amit Etkin describes the independent academic work that has been published on this and explains how ALTO-207, which is a combination of pramipexole and ondansetron, appears to have a more tolerable profile. Plus, an update on two other key programs. Coverage brought to you by

CEO Riad Sherif describes the phase 2 data Oculis delivered in optic neuritis with privosegtor last year and he previews data the company will have soon for licaminlamab in dry eye. Coverage brought to you by

It also announced that the three lead programs will go after small cell lung cancer, ovarian, and hepatocellular carcinoma, though it did not disclose specific targets.